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Gene Patents No More?  Deciphering the Meaning 
of Prometheus 
Dr. Fazal Khan* and Lindsay Kessler**ǂ 
I. INTRODUCTION 
When Congress enacted the United States Patent Act in 1952, it specified 
that patentable subject matter included anything “under the sun that is made 
by man.”1  Three decades ago the United States Patent and Trademark 
Office (USPTO) issued the first gene patent and ushered in a brave new 
gold rush.  Some genes are associated with specific diseases, so being able 
to identify these sequences is an essential first step for developing genomic 
diagnostic tests and therapies.  The problem with gene patents is that they 
allow modern-day prospectors to cordon off access to naturally occurring 
DNA sequences and exclude others from conducting research or developing 
useful applications based on these sequences.  In 2009, a broad coalition of 
plaintiffs challenged Myriad Genetics over its breast cancer gene patents.  
In July 2011, the U.S. Court of Appeals for the Federal Circuit ruled 2-1 in 
 
* Dr. Fazal Khan teaches at University of Georgia School of specializing in health law.  He 
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legal (J.D.) degrees from the Medical Scholars Program at the University of Illinois at 
Urbana-Champaign.  His current research focuses on reform of the American healthcare 
system, the effect of globalization on healthcare and the challenge of regulating emerging 
biotechnologies.  Representative articles and presentations include proposals on: 
administrative regulations to protect against epigenetic harms (and endocrine disruptors) in 
consumer products; ethical regulations on human drug trials in developing countries; 
rethinking public health laws post-9/11 to ensure adequate protection of civil liberties and 
effective emergency response; the potential dissonance between personal health records and 
electronic medical records; and ethical safeguards that would allow organ donation from 
anencephalic infants.   
Dr. Khan and Ms. Kessler would like to thank Kirk Hartley of LSP Group, LLC in Chicago, 
IL for his dedication, passion and inspiration for this article.   
** Lindsay Kessler is an Associate Attorney [November 2012] in the Health Care Practice 
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1.  Jonah D. Jackson, Something Like the Sun: Why Even “Isolated and Purified” Genes 
Are Still Products of Nature, 89 TEX. L. REV. 1453, 1454 (May 2011). 
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favor of upholding Myriad’s gene patents, overturning a lower court 
decision. 
On March 20, 2012, Mayo Collaborative Services v. Prometheus 
Laboratories, Inc.2 (Prometheus) potentially restored sanity on the issue of 
whether gene sequences can be patented. While not addressing gene patents 
specifically, a unanimous Supreme Court correctly reaffirmed that one 
cannot patent “the underlying laws of nature themselves.”3  However, the 
Court explicitly linked its decision to the viability of gene patents when less 
than a week later it vacated the Myriad decision and remanded it back to the 
Federal Circuit to reconsider in light of its ruling in Prometheus. 
While it is not definitively clear that gene patents are dead in light of 
Prometheus, this essay argues that properly understanding the Supreme 
Court’s logic should lead to no other result.4  Predicting whether the 
“patent-friendly” Federal Circuit reaches the same conclusion is not the 
focus of this essay.5  Instead, this essay serves to rebut claims that gene 
patents are consonant with patent law and needed to stimulate genomics 
research and development. 
Through the lens of the Myriad case, we will recount why there was such 
a strong public interest movement against recognizing such patents.  
Specifically, we will show how this particular patent stifles research, 
impedes access to affordable testing, and detrimentally effects future 
developments in the cancer world.  Furthermore, we will briefly examine 
the Supreme Court’s legal reasoning in Prometheus and why it should be 
read as invalidating gene patents. 
II. CHALLENGING MYRIAD 
The ACLU and 20 others initiated the lawsuit against Myriad Genetics 
on May 12, 2009, officially challenging the BRCA1/2 gene patent.  The 
joined parties comprised of researchers, genetic counselors, women 
patients, cancer survivors, breast cancer and women’s health groups, 
scientific associations representing 150,000 geneticists, pathologists and 
laboratory professionals.  Generally, the Plaintiffs pursued attacks on 4 
 
2.  Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 
(2012). 
3.  Prometheus, 132 S. Ct. at 1305.   
4.  Andrew Pollack, Justices Send Back Gene Case, N.Y. TIMES, Mar. 26, 2012, at B1, 
available at http://www.nytimes.com/2012/03/27/business/high-court-orders-new-look-at-
gene-patents.html.   
5.  Myriad’s stock fell the day of the Prometheus decision, as investors feared it meant 
that the Supreme Court was inclined also to rule that genes could not be patented.  However, 
Myriad’s stock rose 56 cents to $23.34 on Monday, perhaps because the Supreme Court will 
now not be hearing the case itself, instead leaving it to the presumably more patent-friendly 
appellate court.  See id.  
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patent categories: (1) patents on natural human genes, (2) patents on genes 
with natural mutations, (3) patents on any method of looking for mutations 
in natural human genes, and (4) patents over the general thought that genes 
are different with different effects, which correlate with an increased risk of 
beast and/or ovarian cancer.6  Before issuing a final opinion, the presiding 
judge denied the Defendants’ motion to dismiss in November of 2009, 
which some understood as Judge Sweet recognizing the case’s importance 
for medical research and innovation.7  Later, on March 29, 2010, the district 
court granted the Plaintiffs’ motion for summary judgment, effectively 
declaring Myriad’s patents invalid based on the theory that they contain 
products of nature and abstract ideas.8  Shortly after, the Defendants 
announced its plans to appeal the decision.9 
On July 29, 2011, the appellate court found for Myriad Genetics, 
reversing in part the prior decision.10  In the majority opinion, the court first 
held that isolated DNA does not stem from products of nature, and therefore 
is patent-eligible.11  Similarly, the “growing and determining method” 
Myriad utilizes for screening potential cancer therapeutics was held valid.12  
However, the “comparing” or “analyzing” diagnostic method used on DNA 
sequences held not patent-eligible, because they involve abstract mental 
processes.13  Yet the court’s decision regarding the products of nature 
doctrine was a close one at 2-1, with a strong dissenting opinion.14  The 
ACLU and Myriad Genetics each filed petitions for rehearings in August 
2011, but both were denied.15  Following this decision, the ACLU filed a 
writ of certiorari to the US Supreme Court,16 on December 6, 2011.17  
 
6.  Marissa Noelle Pins, Impeding Access to Quality Patient Care and Patient Rights: 
How Myriad Genetics’ Gene Patents are Unknowingly Killing Cancer Patients and How to 
Calm the Ripple Effect, 17 J. INTELL. PROP. L. 377, 379 (Spring 2010).   
7.  See Association for Molecular Pathology v. United States Patent and Trademark 
Office, 669 F. Supp. 2d 365 (S.D.N.Y. Nov. 1, 2009) [hereinafter Order to Deny 
Defendants’ Motion to Dismiss]. 
8.  Association for Molecular Pathology v. United States Patent and Trademark Office, 
702 F. Supp. 2d 181 (S.D.N.Y.  2010).   
9.  Pins, supra note 6, at 382. 
10.  Association for Molecular Pathology v. United States Patent and Trademark Office, 
653 F.3d 1329, 1333 (Fed. Cir. 2011). 
11.  Id. at 1350. 
12.  See id. at 1357.   
13.  Id.   
14.  John Conley, ACLU and Myriad Both Seek Further Federal Circuit Review, 
GENOMICS LAW REPORT (Sep. 2, 2011), http://www.genomicslawreport.com/index.php/ 
2011/09/02/aclu-and-myriad-both-seek-further-federal-circuit-review/. 
15.  Id. 
16.  Allison Dobson, Classen: Has the Federal Circuit Lost Interest in Patentable 
Subject Matter?, GENOMICS LAW REPORT (Sep. 14, 2011), 
http://www.genomicslawreport.com/index.php/2011/09/14/classen-has-the-federal-circuit-
lost-interest-in-patentable-subject-matter/. 
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Additionally, the USPTO scheduled two hearings “on independent second 
opinion genetic testing where patents and exclusive licenses exist that cover 
primarily genetic diagnostic tests,” for February 16 and March 9, 2012.18  
As we now know, these hearings are moot following Prometheus. 
III. LEGAL ARGUMENTS 
To be eligible for a patent in the United States, the USPTO must certify 
that the invention meets three separate conditions: (1) it must be novel, (2) 
it must have utility, and (3) it must be nonobvious.19  When it comes to 
biological material, whether genetic or not, much controversy surrounds the 
patent-eligibility of those “inventions” naturally occurring in humans.  
When the Patent Act was enacted in 1952, it included any subject matter 
“under the sun that is made by man.”20  Later, this assertion was modified 
when patents were prohibited on the laws of nature, physical phenomena, 
and abstract ideas and mental processes, otherwise known as the product of 
nature doctrine.21  These three exceptions to patent-eligibility come from a 
1980 United States Supreme Court case, Diamond v. Chakrabarty, which is 
the first and only decision directly addressing the patentability of living 
organisms.22  The Court in Chakrabarty upheld a patent for a laboratory-
created bacterium with properties not found in nature, and two years later 
the USPTO granted its first human genetic material patent.23 
The patent system was originally designed to grant certain rights to 
inventors for their inventions in order to reward and encourage human 
ingenuity.24  But like the ACLU argues, genes are not inventions but rather 
are natural parts of the human body.  In fact, the USPTO recognizes this 
differentiation by maintaining the Chakrabarty exception, that products of 
nature not patentable.25  However, a genetic sequence may qualify if it is 
 
17.  Kevin Noonan, Plaintiffs File Petition for Certiorari in AMP v. USPTO, PATENT 
DOCS (Dec. 8, 2011), http://www.patentdocs.org/2011/12/plaintiffs-file-petition-for-
certiorari-in-amp-vuspto.html?utm_source=feedburner&utm_medium=email&utm_ 
campaign=Feed%3A+PatentDocs+%28Patent+Docs%29.   
18.  Donald Zuhn, USPTO to Hold Hearing on Genetic Diagnostic Testing, PATENT 
DOCS (Feb. 15, 2012), http://www.patentdocs.org/2012/02/uspto-to-hold-hearing-on-genetic-
diagnostic-testing.html?utm_source=feedburner&utm_medium=email&utm_campaign 
=Feed%3A+PatentDocs+%28Patent+Docs%29. 
19.  Pins, supra note 6, at 385.   
20.  Jackson, supra note 1, at 1454. 
21.  Id.  
22.  Id. 
23.  Id. 
24.  AMERICAN CIVIL LIBERTIES UNION, Frequently Asked Questions: Legal Challenge to 
Patenting of Human Genes (Sep. 10, 2010), available at http://www.aclu.org/ 
files/assets/legal_faq_brca.pdf [hereinafter ACLU FAQ].   
25.  Id. 
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“isolated and purified,” through removing the gene from the human body 
and stripping away the “non-coding regions.”26  Yet the ACLU challenges 
the isolation and purification process as applied to human genes, and argues 
that the process is “simple enough for any graduate student in genetics or a 
related field to perform.”27  Therefore, the ACLU analogizes the BRCA1/2 
process to removing gold from a mountain and then patenting the gold, 
therefore violating the ingenuity and non-obvious requirements for 
patentable material.28 
IV. WHY PROMETHEUS SHOULD BE READ AS INVALIDATING GENE 
PATENTS 
Only months after the Supreme Court granted certiorari to Myriad, the 
Court ruled a blood test patent developed by Prometheus invalid, 
reinforcing the “law of nature” doctrine.29  The test at issue looked at the 
chemical reaction after prescribing a drug, enabling a doctor to modify the 
dosage and make the treatment more effective or avoid unwanted side 
effects.30  In a unanimous decision, Justice Breyer wrote that inventors must 
do more than “recite a law of nature and then add the instruction “apply the 
law.”31 As discussed below, the concerns raised by the Court in Prometheus 
are directly applicable to Myriad’s gene patents. 
Myriad Genetics’ strict enforcement of its license created a monopoly in 
the field of BRCA 1/2 testing.  Using its patent power, Myriad has sent 
several cease-and-desist letters to laboratories and researchers throughout 
the United States, telling them to stop testing.32  Out of fear of patent 
infringement penalties, this has resulted in a chilling effect among the 
various parties who deal with diagnostic testing.  Dr. Harry Ostrer, a 
professor of pediatrics, pathology, and medicine, and a plaintiff in the 
case,33 is a working example of this fear that many are experiencing.  Dr. 
Ostrer was unable to provide patients with results of BRCA1/2 tests due to 
Myriad’s patent, something he desired to do, and testified he would do if 
 
26.  Id. 
27.  Id. 
28.  Id. 
29.  Pollack, supra note 4. 
30.  Id. 
31.  Id. 
32.  AMERICAN CIVIL LIBERTIES UNION, Legal Challenge to Human Gene Patents, 2, 6 
(June 27, 2009), http://www.aclu.org/files/pdfs/freespeech/brca_qanda.pdf [hereinafter Legal 
Challenge to Human Gene Patents].  
33.  Plaintiff statement from Harry Ostrer, M.D., AMERICAN CIVIL LIBERTIES UNION, 
BRCA-Plaintiff Statements, (May 12, 2009), http://www.aclu.org/free-speech_womens-
rights/brca-plaintiff-statements#ostrer [hereinafter Ostrer]. 
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the patent was invalidated.34  Dr. Ostrer displayed frustration with the 
BRCA1/2 patent as it currently stands: 
Currently, I am recruiting hundreds of women into a new study to 
identify other genes associated with a risk of breast 
cancer. . .Unfortunately, once such new genes are identified, the use of 
this information in clinical practice could be limited because it might be 
viewed by Myriad Genetics as infringing on its BRCA patentsFalse 
Every day I think about how the findings of the research laboratory can 
be translated into new genetic tests that might benefit, not harm, people.35 
In 2010, Myriad Genetics brought in $353 million (88 percent of their 
total revenue) from the breast cancer test.36  However, the industry has not 
seen any new innovation from Myriad in the past five years, when it last 
introduced the most recent BRCA1/2 test.37  Executives at Myriad say they 
plan to prepare for technological improvements, in response to claims of 
newer DNA-sequencing techniques being faster and less expensive 
compared to the technology that Myriad uses, reportedly from the 1990s.38  
Admittedly, former Myriad employee Sean Tavtigian said that the company 
“is trying to catch up, but it’s going kind of slow.”39 
In fact, Life Technologies has developed a new Proton Sequencer that 
can read an entire person’s genome for $1,00040 - less than Myriad charges 
for just two genes.  A British company, Oxford Nanopore, has followed suit 
and recently introduced the world’s first miniature DNA sequencer and will 
be available commercially this year for $900.41  But because of strict patent 
protection on BRCA1/2, lawyers remain unsure whether other methods, like 
full gene sequencing, would violate Myriad’s patents on the isolated 
genes.42  Some predict that when Myriad’s patents expire, the price of 
whole genome sequencing will trend as low as $100, and single-gene test 
 
34.  Id. 
35.  Declaration of Harry Ostrer, M.D., available at http://docs.justia.com/cases/federal/ 
district-courts/new-york/nysdce/1:2009cv04515/345544/47/0.pdf?ts=1251485192. 
36.  Andrew Pollack, Despite Gene Patent Victory, Myriad Genetics Faces Challenges, 
N.Y. TIMES, Aug. 24, 2011, at B1, available at http://www.nytimes.com/2011/08/25/ 
business/despite-gene-patent-victory-myriad-genetics-faces-challenges.html?pagewanted=all 
[hereinafter Myriad Genetics Faces Challenges]. 
37.  Ostrer, supra note 35.   
38.  Myriad Genetics Faces Challenges, supra note 38. 
39.  Id.  
40.  Clive Cookson, Machine to read individual’s DNA for $1,000, FINANCIAL TIMES 
(Jan. 10, 2012), http://www.ft.com/intl/cms/s/2/e3c6b7bc-3ac3-11e1-a756-
00144feabdc0.html%23axzz1maUoc31U 
41.  Clive Cookson, Oxford Nanopore unveils mini-DNA reader, FINANCIAL TIMES (Feb. 
17, 2012), http://www.ft.com/intl/cms/s/2/318a378a-5900-11e1-b118-00144feab 
dc0.html#axzz1oixikxkx [hereinafter Oxford Nanopore].  
42.  Myriad Genetics Faces Challenges, supra note 38. 
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methods will be moot.43 
In other words, the exact concerns raised by the Supreme Court in 
Prometheus directly support the ACLU in its fight against Myriad.  The 
Court argued that Prometheus’ blood test patent directs a treating physician 
towards a particular course of action, imposing on the sanctity of the 
doctor-patient relationship.  Explicitly the Court recognizes that these 
patents “tie up the doctor’s subsequent treatment” and “threaten to inhibit 
the development of more refined treatment recommendations.”44  Further, 
Prometheus’ patent encourages physicians to discard crucial treatment 
factors such as individual patient characteristics and physician’s own 
medical inferences in favor of a metabolic blood test.45  In the world of 
patent eligibility, Prometheus forces applicants and courts to reconsider the 
law of nature prohibition, as opposed to the equally controversial novelty, 
and non-obviousness requirements. 
V.  CONCLUSION 
Before Prometheus, gene patent opponents faced an uphill battle.  With 
almost thirty years of patent law affirming the patentability of genes46 and a 
struggling economy, companies like Myriad Genetics have found a source 
of revenue they will fight to protect.  While some earlier predicted that the 
USPTO is not ready to change its standards,47 Prometheus has changed the 
analytical framework regarding human gene patents. 
Myriad Genetics cautioned about the negative repercussions that would 
result in finding for the Plaintiffs, claiming that the entire foundation of the 
biotechnology industry would unravel if human gene patents were 
invalidated.48  This facile argument overlooks the advantages that could 
result if other companies are allowed to compete.  Most importantly, the 
cancer patients who need access to the BRCA1/2 test would have more 
affordable insurance options because more laboratories would offer the test.  
For individuals like Vicky Thomason who are unable to pay for BRCA1/2, 
and “get up every day not knowing if [they] have a mutation,”49 this can 
make an incredible difference.  The possibilities are endless if Myriad’s 
 
43.  THE ECONOMIST, More harm than good? Patenting genes is bad for diagnosis, Apr. 
15, 2010, available at http://www.economist.com/node/15905837?story_id=15905837. 
44.  Prometheus, 132 S. Ct. at 1302.   
45.  Id. 
46.  Jackson, supra note 1, at 1487.   
47.  Id.   
48.  Miri Yoon, Gene Patenting Debate: The Meaning of Myriad, 9 J. MARSHALL REV. 
INTELL. PROP. L. 953, 973-74 (Spring 2010).  
49.  Plaintiff statement from Vicky Thomason.  AMERICAN CIVIL LIBERTIES UNION, 
BRCA-Plaintiff Statements, (May, 12,2009) http://www.aclu.org/free-speech_womens-
rights/brca-plaintiff-statements#thomason. 
26 Annals of Health Law Informed Consent [Vol. 2 
gene exclusivity ends: researchers would gain access to valuable data, more 
efficient testing methods could be developed, and future developments on 
the BRCA1/2 gene would not be seen as patent infringement.  For the first 
time in patent history, the ACLU is questioning a human gene patent on 
constitutional grounds.50 
Arguably, the Supreme Court granted certiorari in Myriad for the limited 
purpose of vacating and remanding the case for consideration in light of 
Prometheus.51 Prometheus directly contradicts the appellate court’s 
decision to uphold Myriad’s patents.  With the case on remand, hopefully 
the court will follow Prometheus’ lead and set new precedent for human 
gene patent litigation in the future.  Once the natural phenomena component 
of Myriad’s claims are stripped away, the court will consider the Myriad’s 
contribution to the BRCA1/2 test.52  “It then comes down to whether 
Myriad added anything non-routine or non-conventional, beyond that law 
of nature, to make it patentable.”53  More crucial to the Court is the concern 
that scientists are unable to do research without infringing on the BRCA1/2 
patent - not only does Myriad’s exclusivity stifle innovation and cancer 
research, but also it intrudes on the practice of medicine as a profession.54  
After Prometheus, there is now real hope that gene patents will not impede 
the progress of researchers and medical professionals seeking to help 
patients through a better understanding and application of nature’s laws. 
 
 
50.  Ann Weilbaecher, Can Patent Protections Trample Civil Liberties? The ACLU 
Challenges the Patentability of Breast Cancer Genes, 15 PUB. INT. L. REP. 10, 17 (2009). 
51.  John Conley & Dan Vorhaus, Myriad Finally Reaches the Supreme Court (But Only 
For a Moment), GENOMICS LAW REPORT (Mar. 27, 2012), http:// 
www.genomicslawreport.com/index.php/2012/03/27/myriad-finally-reaches-the-supreme-
court-but-only-for-a-moment/. 
52.  See Christine Livoti, Myriad’s gene patents case may still end up at Supreme Court, 
FINANCIAL TIMES (Apr. 3, 2012), http://www.ft.com/intl/cms/s/2/ebad0c7a-7dca-11e1-9adc-
00144feab49a.html#axzz1rg2V5HoW. 
53.  Id. 
54.  See id. 
